323 related articles for article (PubMed ID: 30907723)
21. Lytic cycle switches of oncogenic human gammaherpesviruses.
Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
[TBL] [Abstract][Full Text] [Related]
22. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
[TBL] [Abstract][Full Text] [Related]
23. [Effects of Epstein-Barr virus on host gene expression in Burkitt's lymphoma cell lines].
Broderick P; Hubank M; Sinclair A
Ai Zheng; 2009 Aug; 28(8):813-21. PubMed ID: 19664326
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds.
Matusali G; Arena G; De Leo A; Di Renzo L; Mattia E
Mol Cancer; 2009 Mar; 8():18. PubMed ID: 19272151
[TBL] [Abstract][Full Text] [Related]
25. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus.
Yu X; Wang Z; Mertz JE
PLoS Pathog; 2007 Dec; 3(12):e194. PubMed ID: 18085824
[TBL] [Abstract][Full Text] [Related]
26. Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency.
Wu TT; Usherwood EJ; Stewart JP; Nash AA; Sun R
J Virol; 2000 Apr; 74(8):3659-67. PubMed ID: 10729142
[TBL] [Abstract][Full Text] [Related]
27. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
28. Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
Mori T; Sairenji T
Virus Genes; 2006 Jun; 32(3):327-34. PubMed ID: 16732486
[TBL] [Abstract][Full Text] [Related]
29. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.
Kis LL; Salamon D; Persson EK; Nagy N; Scheeren FA; Spits H; Klein G; Klein E
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):872-7. PubMed ID: 20080768
[TBL] [Abstract][Full Text] [Related]
30. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
31. Role of the TSG101 gene in Epstein-Barr virus late gene transcription.
Chua HH; Lee HH; Chang SS; Lu CC; Yeh TH; Hsu TY; Cheng TH; Cheng JT; Chen MR; Tsai CH
J Virol; 2007 Mar; 81(5):2459-71. PubMed ID: 17182691
[TBL] [Abstract][Full Text] [Related]
32. The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.
Chen H; Lee JM; Wang Y; Huang DP; Ambinder RF; Hayward SD
Proc Natl Acad Sci U S A; 1999 Aug; 96(16):9339-44. PubMed ID: 10430944
[TBL] [Abstract][Full Text] [Related]
33. Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter.
Lavens S; Faust EA; Lu F; Jacob M; Leta M; Lieberman PM; Puré E
J Virol; 2004 Aug; 78(16):8543-51. PubMed ID: 15280463
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Epstein-Barr virus reactivation in a modeled spaceflight system.
Brinley AA; Theriot CA; Nelman-Gonzalez M; Crucian B; Stowe RP; Barrett AD; Pierson DL
J Cell Biochem; 2013 Mar; 114(3):616-24. PubMed ID: 22991253
[TBL] [Abstract][Full Text] [Related]
35. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
36. Viral response to chemotherapy in endemic burkitt lymphoma.
Tang W; Harmon P; Gulley ML; Mwansambo C; Kazembe PN; Martinson F; Wokocha C; Kenney SC; Hoffman I; Sigel C; Maygarden S; Hoffman M; Shores C
Clin Cancer Res; 2010 Apr; 16(7):2055-64. PubMed ID: 20233888
[TBL] [Abstract][Full Text] [Related]
37. Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.
Chang Y; Lee HH; Chang SS; Hsu TY; Wang PW; Chang YS; Takada K; Tsai CH
J Virol; 2004 Dec; 78(23):13028-36. PubMed ID: 15542654
[TBL] [Abstract][Full Text] [Related]
38. Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: implications for therapy of EBV associated tumors.
Chen C; Li D; Guo N
Cancer Biol Ther; 2009 Jun; 8(11):987-95. PubMed ID: 19448399
[TBL] [Abstract][Full Text] [Related]
39. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin.
Goldfeld AE; Liu P; Liu S; Flemington EK; Strominger JL; Speck SH
Virology; 1995 May; 209(1):225-9. PubMed ID: 7538254
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Epstein-Barr virus lytic cycle by protoapigenone.
Tung CP; Chang FR; Wu YC; Chuang DW; Hunyadi A; Liu ST
J Gen Virol; 2011 Aug; 92(Pt 8):1760-1768. PubMed ID: 21490247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
